Product description
» Proprietary strain: Pylopass® is a Lactobacillus reuteri DSMZ 17648, which
specifically binds and coaggregates with H. pylori to reduce the bacterial load.
» Efficiency: Pylopass® decrease the risk of developing gastritis and peptic ulcer
disease and can increase the efficacy of Antibiotics treatment. » No side effects: Pylopass® does not alter the microflora of the gut and does not
contribute to the antibiotic resistance.
Reduction of
H. pylori load
in 60% of the
subjects in only
2 weeks
Patented Mechanism of Action: Pylopass® is able to recognize surface
structures on H. pylori and to form coaggregates. Those Co-aggregates are
eliminated from the organism through
the gastrointestinal tract. This leads to
a reduction of Helicobacter pylori load
in the stomach.
Read more